دورية أكاديمية
[Long-term follow-up of childhood low-risk ALL patients treated with SCMC-ALL-2005 protocol].
| العنوان: | [Long-term follow-up of childhood low-risk ALL patients treated with SCMC-ALL-2005 protocol]. |
|---|---|
| المؤلفون: | Hu WT; Shanghai Children's Medical Center, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China., Xue HL, Chen J, Pan C, Shen SH, Zhou M, Ye QD, Jiang H, Luo CY, Tang YJ, Wang JM, Gu LJ, Tang JY |
| المصدر: | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi [Zhonghua Xue Ye Xue Za Zhi] 2013 Oct; Vol. 34 (10), pp. 834-8. |
| نوع المنشور: | English Abstract; Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | Chinese |
| بيانات الدورية: | Publisher: Chinese Medical Association Country of Publication: China NLM ID: 8212398 Publication Model: Print Cited Medium: Print ISSN: 0253-2727 (Print) Linking ISSN: 02532727 NLM ISO Abbreviation: Zhonghua Xue Ye Xue Za Zhi Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Beijing : Chinese Medical Association Original Publication: Beijing : Zhongguo yi xue ke xue yuan. |
| مواضيع طبية MeSH: | Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/*mortality, Child ; Child, Preschool ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Infant ; Male ; Treatment Outcome |
| مستخلص: | Objective: To evaluate the long-term efficacy of SCMC-ALL-2005 protocol in treatment of low-risk childhood acute lymphoblastic leukemia (ALL). Methods: From May 1, 2005 to April 30, 2009, 387 patients enrolled into SCMC-ALL-2005 protocol. Based on the characteristics of cell morphology, immunology, cytogenetics and molecular biology and treatment response, 158 patients were fit into the low-risk treatment group. All the cases were registered in pediatric oncology network database (POND). The clinical characteristics and outcome were analyzed. Results: Until December 31, 2012, the 5-year event free survival (EFS) and overall survival (OS) is (77.76±3.37)% and (89.55±2.83)%, respectively. Median follow-up time is 5.33 y (3.75-7.70 y). Five patients (3.16%) died of complication, all of them were severe infections. Twenty-seven patients (17.09%) relapsed, including 13 bone marrow relapse (8.23%), 5 testis relapse (5.32% of boys, 2 of unilateral and 3 bilateral), 6 central nerve system relapse (CNS, 3.80%), 1 relapse in both bone marrow and CNS, 1 relapse in both bone marrow and testis, and 1 right ovary and fallopian tube relapse. Relapse is related to positive minimal residual disease. Two cases (1.27%) occurred second tumors, 4 patients (2.53%) gave up treatment in complete remission without special reasons. Conclusion: The EFS and life quality of SCMC-ALL-2005 protocol in the treatment of childhood low-risk ALL is satisfactory. The treatment-related mortality rate is lower, and the long-term EFS is higher than that of XH-99 protocol. |
| تواريخ الأحداث: | Date Created: 20131101 Date Completed: 20150423 Latest Revision: 20131031 |
| رمز التحديث: | 20240829 |
| DOI: | 10.3760/cma.j.issn.0253-2727.2013.10.003 |
| PMID: | 24171955 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0253-2727 |
|---|---|
| DOI: | 10.3760/cma.j.issn.0253-2727.2013.10.003 |